Emergent Biosolutions Inc (NYSE:EBS) price on Friday, May 02, rose 4.47% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.14.
A look at the stock’s price movement, the close in the last trading session was $4.92, moving within a range at $4.94 and $5.295. The beta value (5-Year monthly) was 2.147. Turning to its 52-week performance, $15.10 and $2.82 were the 52-week high and 52-week low respectively. Overall, EBS moved -0.58% over the past month.
Emergent Biosolutions Inc’s market cap currently stands at around $279.29 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-02.
Analysts have a consensus estimate of 218.5M for the company’s revenue for the quarter, with a low and high estimate of 200M and 237M respectively. The average forecast suggests down to a -27.26% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 819.44M, representing a -21.48% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that EBS is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend EBS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
EBS’s current price about 6.61% and -6.14% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 49.20, while 7-day volatility ratio is 7.08% and 8.09% in the 30-day chart. Further, Emergent Biosolutions Inc (EBS) has a beta value of 2.08, and an average true range (ATR) of 0.40. Analysts have given the company’s stock an average 52-week price target of $51.5, forecast between a low of $38 and high of $65. Looking at the price targets, the low is -639.3% off current price level while to achieve the yearly target high, price needs to move -1164.59%. Nonetheless, investors will most likely welcome a -901.95% jump to $51.5 which is the analysts’ median price.
If we refocus on Emergent Biosolutions Inc (NYSE:EBS), historical trading data shows that trading volumes averaged 1.06 over the past 10 days and 1.23 million over the past 3 months. The company’s latest data on shares outstanding shows there are 54.30 million shares.
The 3.72% of Emergent Biosolutions Inc’s shares are in the hands of company insiders while institutional holders own 64.27% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 9.02 million on 2025-04-15, giving us a short ratio of 7.35. The data shows that as of 2025-04-15 short interest in Emergent Biosolutions Inc (EBS) stood at 1678.0000999999997 of shares outstanding, with shares short falling to 9.16 million registered in 2025-03-14. Current price change has pushed the stock -46.23% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the EBS stock continues to rise going into the next quarter.
